Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] price plunged by -0.62 percent to reach at -$0.05.
The one-year BCYC stock forecast points to a potential upside of 69.71. The average equity rating for BCYC stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Bicycle Therapeutics Plc ADR [BCYC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCYC shares is $26.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCYC stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Bicycle Therapeutics Plc ADR shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on November 08, 2024. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Outperform. The new note on the price target was released on September 06, 2024, representing the official price target for Bicycle Therapeutics Plc ADR stock. Previously, the target price had yet another drop from $33 to $28, while B. Riley Securities kept a Neutral rating on BCYC stock.
The Average True Range (ATR) for Bicycle Therapeutics Plc ADR is set at 0.55, with the Price to Sales ratio for BCYC stock in the period of the last 12 months amounting to 21.63. The Price to Book ratio for the last quarter was 0.75, with the Price to Cash per share for the same quarter was set at 11.46.
BCYC Stock Performance Analysis:
Bicycle Therapeutics Plc ADR [BCYC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.62. With this latest performance, BCYC shares dropped by -6.40% in over the last four-week period, additionally sinking by -60.69% over the last 6 months – not to mention a drop of -62.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCYC stock in for the last two-week period is set at 46.98, with the RSI for the last a single of trading hit 45.92, and the three-weeks RSI is set at 46.22 for Bicycle Therapeutics Plc ADR [BCYC]. The present Moving Average for the last 50 days of trading for this stock 8.25, while it was recorded at 8.27 for the last single week of trading, and 16.33 for the last 200 days.
Insight into Bicycle Therapeutics Plc ADR Fundamentals:
Bicycle Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.86 and a Current Ratio set at 14.86.
BCYC Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCYC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bicycle Therapeutics Plc ADR go to -11.21%.
Bicycle Therapeutics Plc ADR [BCYC] Institutonal Ownership Details
There are presently around $93.79%, or 95.18%% of BCYC stock, in the hands of institutional investors. The top three institutional holders of BCYC stocks are: BAKER BROS. ADVISORS LP with ownership of 9.4 million shares, which is approximately 18.0796%. DEEP TRACK CAPITAL, LP, holding 3.49 million shares of the stock with an approximate value of $$70.65 million in BCYC stocks shares; and DEEP TRACK CAPITAL, LP, currently with $$45.6 million in BCYC stock with ownership which is approximately 4.3334%.
